ATE411293T1 - Kondensierte azabicyclische verbindungen, die den vanilloidrezeptorsubtyp 1 (vr1)- rezeptor inhibieren - Google Patents

Kondensierte azabicyclische verbindungen, die den vanilloidrezeptorsubtyp 1 (vr1)- rezeptor inhibieren

Info

Publication number
ATE411293T1
ATE411293T1 AT04780017T AT04780017T ATE411293T1 AT E411293 T1 ATE411293 T1 AT E411293T1 AT 04780017 T AT04780017 T AT 04780017T AT 04780017 T AT04780017 T AT 04780017T AT E411293 T1 ATE411293 T1 AT E411293T1
Authority
AT
Austria
Prior art keywords
sub
receptor
condensed
inhibit
azabicyclic compounds
Prior art date
Application number
AT04780017T
Other languages
English (en)
Inventor
Erol Bayburt
Stanley Didomenico
Irene Drizin
Arthur Gomtsyan
John Koenig
Richard Penner
Robert Schmidt
Sean Turner
Tammie White
Guo Zhu Zheng
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/364,210 external-priority patent/US7074805B2/en
Application filed by Abbott Lab filed Critical Abbott Lab
Application granted granted Critical
Publication of ATE411293T1 publication Critical patent/ATE411293T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/28—Cinnolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
AT04780017T 2003-02-11 2004-08-04 Kondensierte azabicyclische verbindungen, die den vanilloidrezeptorsubtyp 1 (vr1)- rezeptor inhibieren ATE411293T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/364,210 US7074805B2 (en) 2002-02-20 2003-02-11 Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
US10/634,678 US6933311B2 (en) 2003-02-11 2003-08-05 Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor

Publications (1)

Publication Number Publication Date
ATE411293T1 true ATE411293T1 (de) 2008-10-15

Family

ID=32824388

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04780017T ATE411293T1 (de) 2003-02-11 2004-08-04 Kondensierte azabicyclische verbindungen, die den vanilloidrezeptorsubtyp 1 (vr1)- rezeptor inhibieren

Country Status (14)

Country Link
US (1) US6933311B2 (de)
EP (1) EP1660455B1 (de)
JP (1) JP2007501246A (de)
KR (1) KR20070026291A (de)
CN (1) CN1863777A (de)
AT (1) ATE411293T1 (de)
AU (1) AU2004265306A1 (de)
BR (1) BRPI0413305A (de)
CA (1) CA2534542A1 (de)
DE (1) DE602004017196D1 (de)
ES (1) ES2315704T3 (de)
MX (1) MXPA06001396A (de)
WO (1) WO2005016890A1 (de)
ZA (1) ZA200601022B (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7074805B2 (en) * 2002-02-20 2006-07-11 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
CA2476936A1 (en) * 2002-02-20 2003-08-28 Chih-Hung Lee Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor
US6933311B2 (en) * 2003-02-11 2005-08-23 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
US7015233B2 (en) * 2003-06-12 2006-03-21 Abbott Laboratories Fused compounds that inhibit vanilloid subtype 1 (VR1) receptor
GB0322016D0 (en) * 2003-09-19 2003-10-22 Merck Sharp & Dohme New compounds
US20070004679A1 (en) * 2004-05-17 2007-01-04 Nathalie Schlienger Androgen receptor modulators and methods of treating disease using the same
US7268232B2 (en) * 2004-05-17 2007-09-11 Acadia Pharmaceuticals Inc. Androgen receptor modulators and method of treating disease using the same
US20060035939A1 (en) * 2004-07-14 2006-02-16 Japan Tobacco Inc. 3-Aminobenzamide compounds and inhibitors of vanilloid receptor subtype 1 (VR1) activity
RU2392278C2 (ru) * 2004-07-15 2010-06-20 Джапан Тобакко Инк. Конденсированное производное бензамида и ингибитор активности подтипа 1 рецептора ваниллоида (vr1)
MX2007008334A (es) * 2005-01-10 2007-09-11 Acadia Pharm Inc Derivados aminofenilo como moduladores de receptor de androgeno selectivos.
US20060173037A1 (en) * 2005-01-10 2006-08-03 Nathalie Schlienger Aminophenyl derivatives as selective androgen receptor modulators
US7297700B2 (en) * 2005-03-24 2007-11-20 Renovis, Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
DE102005023943A1 (de) 2005-05-20 2006-11-23 Grünenthal GmbH Pentafluorsulfanyl-substituierte Verbindung und deren Verwendung zur Herstellung von Arzneimitteln
JP2009511465A (ja) 2005-10-07 2009-03-19 グレンマーク・ファーマシューティカルズ・エスエー 置換ベンゾ縮合誘導体およびバニロイド受容体リガンドとしてのその使用
WO2007073405A1 (en) * 2005-12-21 2007-06-28 Decode Genetics Ehf N-linked aryl heteroaryl inhibitors of lta4h for treating inflammation
US7906508B2 (en) * 2005-12-28 2011-03-15 Japan Tobacco Inc. 3,4-dihydrobenzoxazine compounds and inhibitors of vanilloid receptor subtype 1 (VRI) activity
CA2643983A1 (en) * 2006-02-21 2007-08-30 Amgen, Inc. Cinnoline derivatives as phosphodiesterase 10 inhibitors
EP1996574A1 (de) * 2006-03-08 2008-12-03 Amgen Inc. Chinolin- und isochinolinderivate als phosphodiesterase-10-inhibitoren
CA2652307A1 (en) * 2006-04-10 2007-10-18 Painceptor Pharma Corporation Compositions and methods for modulating gated ion channels
WO2007120083A1 (en) * 2006-04-13 2007-10-25 Astrazeneca Ab The use of carboxamide derivatives in the manufacture of a medicament for the treatment of inflammatory, allergic and dermatological conditions
CA2647256A1 (en) * 2006-04-18 2007-10-25 Abbott Laboratories Antagonists of the vanilloid receptor subtype 1 (vr1) and uses thereof
TW200824687A (en) * 2006-08-25 2008-06-16 Abbott Lab Compounds that inhibit TRPV1 and uses thereof
US20080153845A1 (en) * 2006-10-27 2008-06-26 Redpoint Bio Corporation Trpv1 antagonists and uses thereof
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
JP2010513557A (ja) * 2006-12-20 2010-04-30 アボット・ラボラトリーズ 疼痛治療のためのｔｒｐｖ１バニロイド受容体アンタゴニストとしてのｎ−（５，６，７，８−テトラヒドロナフタレン−１−イル）尿素誘導体および関連化合物
KR20100016593A (ko) * 2007-04-16 2010-02-12 그뤼넨탈 게엠베하 신규한 바닐로이드 수용체 리간드 및 약제의 제조를 위한 이의 용도
DE102007018151A1 (de) 2007-04-16 2008-10-23 Günenthal GmbH Neue Vanilloid-Rezeptor Liganden und ihre Verwendung zur Herstellung von Arzneimitteln
DE102007018149A1 (de) 2007-04-16 2008-10-23 Grünenthal GmbH Neue Vanilloid-Rezeptor Liganden und ihre Verwendung zur Herstellung von Arzneimitteln
WO2009081222A1 (en) 2007-12-21 2009-07-02 Glenmark Pharmaceuticals, S.A. Substituted tricyclic pyridine or pyrimidine vanilloid receptor ligands
EP2323989A4 (de) * 2008-03-20 2011-06-22 Abbott Lab Verfahren zur herstellung von auf das zentrale nervensystem wirkenden mitteln, bei denen es sich um trpv1-antagonisten handelt
CN101983197B (zh) 2008-04-18 2015-04-22 大熊制药株式会社 新型苯并噁嗪苯并咪唑衍生物、含有该衍生物的药物组合物及其用途
CA2761639C (en) * 2009-05-29 2016-06-07 Raqualia Pharma Inc. Aryl substituted carboxamide derivatives as calcium or sodium channel blockers
US9452980B2 (en) * 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
EP2377850A1 (de) * 2010-03-30 2011-10-19 Pharmeste S.r.l. TRPV1-Vanilloidrezeptorantagonisten mit einem bizyklischen Teil
MX2012012204A (es) 2010-04-22 2012-12-05 Vertex Pharma Proceso para producir compuestos de cicloalquilcarboxamido-indol.
KR101293384B1 (ko) 2010-10-13 2013-08-05 주식회사 대웅제약 신규 피리딜 벤조옥사진 유도체, 이를 포함하는 약학 조성물 및 이의 용도
US8802711B2 (en) * 2011-03-25 2014-08-12 Abbvie Inc. TRPV1 antagonists
FR3016031B1 (fr) 2013-12-26 2016-02-05 Grdf Teledistribution d'une mise a jour logicielle a des terminaux de tele-releve
ES2957761T3 (es) 2014-04-15 2024-01-25 Vertex Pharma Composiciones farmacéuticas para el tratamiento de enfermedades mediadas por el regulador de la conductancia transmembrana de fibrosis quística
CR20180443A (es) 2016-03-17 2018-11-21 Hoffmann La Roche Derivado de morfolina
CN105906564B (zh) * 2016-05-05 2018-11-30 海南省药物研究所 化合物、制备方法及其用途
CA3056970A1 (en) 2017-03-21 2018-09-27 Bayer Pharma Aktiengesellschaft 2-methyl-quinazolines
EP3781565A1 (de) 2018-04-18 2021-02-24 Bayer Pharma Aktiengesellschaft 2-methyl-aza-chinazoline
DE102022104759A1 (de) 2022-02-28 2023-08-31 SCi Kontor GmbH Co-Kristall-Screening Verfahren, insbesondere zur Herstellung von Co-Kristallen

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1344579A (fr) 1961-11-23 1963-11-29 Sandoz Sa Nouveaux dérivés de l'indole et leur préparation
US3647910A (en) * 1970-03-20 1972-03-07 Standard Oil Co Ohio Dehydrogenation of hydrocarbons employing a catalyst of iron oxide-containing activated carbon
US3711610A (en) * 1971-06-01 1973-01-16 Sterling Drug Inc Anticoccidiosis method and compositions involving indazolylphenylureas and indazolylphenylthioureas
US3814711A (en) 1971-07-26 1974-06-04 Mallinckrodt Chemical Works 10-acetamido-s-triazolo-(3,4-a)-isoquinolines
NL7902993A (nl) 1978-04-24 1979-10-26 Rhone Poulenc Ind Nieuwe isochinolinederivaten, de bereiding ervan en farmaceutische preparaten, die de nieuwe isochinoline- derivaten bevatten.
JPS5587771A (en) * 1978-12-27 1980-07-02 Teikoku Hormone Mfg Co Ltd 1-phenylisoquinoline derivative
EP0189473B1 (de) * 1984-08-15 1992-05-27 Schering Aktiengesellschaft Neue dopamin-derivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
JPS62116559A (ja) * 1985-11-18 1987-05-28 Sagami Chem Res Center ４−アシルメチリデン−４，５，６，７−テトラヒドロインド−ル誘導体及びその製造方法
MX22406A (es) 1989-09-15 1994-01-31 Pfizer Nuevos derivados de n-aril y n-heteroarilamidas y urea como inhibidores de acil coenzima a: acil transferasa del colesterol (acat).
EP0518961A1 (de) 1990-03-07 1992-12-23 Aventis Pharma S.A. Glycinamidderivate, ihre herstellung und diese enthaltende arzneimittel
US5362878A (en) * 1991-03-21 1994-11-08 Pfizer Inc. Intermediates for making N-aryl and N-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme A: cholesterol acyl transferase (ACAT)
US5444038A (en) * 1992-03-09 1995-08-22 Zeneca Limited Arylindazoles and their use as herbicides
GB9307833D0 (en) * 1993-04-15 1993-06-02 Glaxo Inc Modulators of cholecystokinin and gastrin
PL328094A1 (en) * 1996-01-16 1999-01-04 Bristol Myers Squibb Co Conformingly restricted aromatic inhibitors triglycerides carrying chromosome protein and method of obtaining such inhibitors
US5760246A (en) * 1996-12-17 1998-06-02 Biller; Scott A. Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method
EP1154989B1 (de) * 1999-02-22 2005-12-14 Pacific Corporation Vanilloid-analoge die resiniferatoxin-pharmacophore enthalten als wirksame vanilloid rezeptor agonisten und analgetika, zusammensetzungen und ihre verwendung
EP1177188B1 (de) * 1999-05-12 2005-10-12 Ortho-McNeil Pharmaceutical, Inc. Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen
YU54202A (sh) * 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
NZ521192A (en) * 2000-03-09 2005-01-28 Ono Pharmaceutical Co Indole derivatives, process for preparation of the same and use thereof
MXPA03000458A (es) * 2000-07-20 2004-06-02 Neurogen Corp Ligandos receptores de capsaicina.
US7199147B2 (en) * 2001-06-12 2007-04-03 Dainippon Sumitomo Pharma Co., Ltd. Rho kinase inhibitors
JP2005501873A (ja) * 2001-07-31 2005-01-20 バイエル・ヘルスケア・アクチェンゲゼルシャフト アミン誘導体
TWI283665B (en) * 2001-09-13 2007-07-11 Smithkline Beecham Plc Novel urea compound, pharmaceutical composition containing the same and its use
GB0130550D0 (en) * 2001-12-20 2002-02-06 Smithkline Beecham Plc Novel compounds
CA2476936A1 (en) * 2002-02-20 2003-08-28 Chih-Hung Lee Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor
GB0206876D0 (en) 2002-03-22 2002-05-01 Merck Sharp & Dohme Therapeutic agents
US6933311B2 (en) * 2003-02-11 2005-08-23 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor

Also Published As

Publication number Publication date
US20040157849A1 (en) 2004-08-12
ZA200601022B (en) 2007-05-30
BRPI0413305A (pt) 2006-10-10
EP1660455A1 (de) 2006-05-31
MXPA06001396A (es) 2007-02-13
CA2534542A1 (en) 2005-02-24
KR20070026291A (ko) 2007-03-08
AU2004265306A1 (en) 2005-02-24
EP1660455B1 (de) 2008-10-15
CN1863777A (zh) 2006-11-15
DE602004017196D1 (de) 2008-11-27
US6933311B2 (en) 2005-08-23
JP2007501246A (ja) 2007-01-25
ES2315704T3 (es) 2009-04-01
WO2005016890A1 (en) 2005-02-24

Similar Documents

Publication Publication Date Title
ATE411293T1 (de) Kondensierte azabicyclische verbindungen, die den vanilloidrezeptorsubtyp 1 (vr1)- rezeptor inhibieren
ATE420644T1 (de) Kondensierte azabicyclischeverbindungen als inhibitoren des vanilloid-rezeptors 1 (vr1)
MY144307A (en) Antagonists of the vanilloid receptor subtype 1 (vr1) and uses thereof
DK1501507T3 (da) Tetrahydropyranyl-cyclopentyl-tertrahydropyridopyrindin-modulatorer af kemokin-receptor-aktivitet
WO2006062981A3 (en) Antagonists to the vanilloid receptor subtype 1 (vr1) and uses thereof
ATE469892T1 (de) Substituierte 1h-dihydropyrazole, ihre herstellung und verwendung
GB0504828D0 (en) Therapeutic agents
MX2007007100A (es) Benzisotiazol-1,1-dioxido que actua como antagonistas para el subtipo 1 del receptor de vanilloida (vr1) y usos de los mismos.
WO2005013894A3 (en) Benzodiazepine cgrp receptor antagonists
WO2004013120A8 (en) Novel benzodioxoles
EA200501333A1 (ru) 5,7-ДИАМИНОПИРАЗОЛО[4,3-d]ПИРИМИДИНЫ, ПОЛЕЗНЫЕ ПРИ ЛЕЧЕНИИ ГИПЕРТЕНЗИИ
GB9929552D0 (en) Compounds
DE602004030334D1 (de) Synthese von 5-substituierten 7-azaindolen und 7-azaindolinen
BR0213140A (pt) Fungicidas de pirazol-pirimidina
WO2005040121A3 (en) Amides that inhibit vanilloid receptor subtype 1 (vr1) receptor
WO2005000807A3 (en) Benzodiazepine cgrp receptor antagonists
GB0030305D0 (en) Compounds
DE60126978D1 (de) Inhibitoren von serin proteasen
SE9904108D0 (sv) Nya föreningar
MXPA03010586A (es) N-[(1s)-1,2,3,4-tertrahidro-1-naftalenil benzamidas trisubtituidas, las cuales inhiben receptores que contienen p2x2/3.
TR200201128T2 (tr) PDE4 inhibitörleri olarak tetrahidrotiyopiranfitalazinon türevleri.
DE60215637D1 (de) Tri- und tetraaza-acenaphthylen-derivate als crf-rezeptor-antagonisten
DE60100811D1 (de) Crf rezeptor-antagonisten und darauf bezogene methoden
MXPA04004980A (es) Antagonistas del receptor ccr-3.
DE60227113D1 (de) Kondensierte camptothecine als antitumormittel

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties